Protein Microarrays Printed from DNA Microarrays

Author(s):  
Oda Stoevesandt ◽  
Mingyue He ◽  
Michael J. Taussig
Author(s):  
Oda Stoevesandt ◽  
Michael J. Taussig ◽  
Mingyue He

2013 ◽  
Vol 6 (8) ◽  
pp. 087001 ◽  
Author(s):  
Manish Biyani ◽  
Junpei Moriyasu ◽  
Yoko Tanaka ◽  
Shusuke Sato ◽  
Shingo Ueno ◽  
...  

2021 ◽  
Author(s):  
Sophie Bérubé ◽  
Tamaki Kobayashi ◽  
Amy Wesolowski ◽  
Douglas E. Norris ◽  
Ingo Ruczinski ◽  
...  

AbstractTechnical variation, or variation from non-biological sources, is present in most laboratory assays. Correcting for this variation enables analysts to extract a biological signal that informs questions of interest. However, each assay has different sources and levels of technical variation and the choice of correction methods can impact downstream analyses. Compared to similar assays such as DNA microarrays, relatively few methods have been developed and evaluated for protein microarrays, a versatile tool for measuring levels of various proteins in serum samples. Here, we propose a pre-processing pipeline to correct for some common sources of technical variation in protein microarrays. The pipeline builds upon an existing normalization method by using controls to reduce technical variation. We evaluate our method using data from two protein microarray studies, and by simulation. We demonstrate that pre-processing choices impact the fluorescent-intensity based ranks of proteins, which in turn, impact downstream analysis.1Impact StatementProtein microarrays are in wide use in cancer research, infectious disease diagnostics and biomarker identification. To inform research and practice in these and other fields, technical variation must be corrected using normalization and pre-processing. Current protein microarray studies use a variety of normalization methods, many of which were developed for DNA microarrays, and therefore are based on assumptions and data that are not ideal for protein microarrays. To address this issue, we develop, evaluate, and implement a pre-processing pipeline that corrects for technical variation in protein microarrays. We show that pre-processing and normalization directly impact the validity of downstream analysis, and protein-specific approaches are essential.


2009 ◽  
Vol 25 ◽  
pp. S360
Author(s):  
O. Stoevesandt ◽  
M. He ◽  
M.J. Taussig

2010 ◽  
Vol 56 (3) ◽  
pp. 376-387 ◽  
Author(s):  
Xiaobo Yu ◽  
Nicole Schneiderhan-Marra ◽  
Thomas O Joos

Abstract Background: Over the last 10 years, DNA microarrays have achieved a robust analytical performance, enabling their use for analyzing the whole transcriptome or for screening thousands of single-nucleotide polymorphisms in a single experiment. DNA microarrays allow scientists to correlate gene expression signatures with disease progression, to screen for disease-specific mutations, and to treat patients according to their individual genetic profiles; however, the real key is proteins and their manifold functions. It is necessary to achieve a greater understanding of not only protein function and abundance but also their role in the development of diseases. Protein concentrations have been shown to reflect the physiological and pathologic state of an organ, tissue, or cells far more directly than DNA, and proteins can be profiled effectively with protein microarrays, which require only a small amount of sample material. Content: Protein microarrays have become well-established tools in basic and applied research, and the first products have already entered the in vitro diagnostics market. This review focuses on protein microarray applications for biomarker discovery and validation, disease diagnosis, and use within the area of personalized medicine. Summary: Protein microarrays have proved to be reliable research tools in screening for a multitude of parameters with only a minimal quantity of sample and have enormous potential in applications for diagnostic and personalized medicine.


2011 ◽  
Vol 81 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Joel Deneau ◽  
Taufeeq Ahmed ◽  
Roger Blotsky ◽  
Krzysztof Bojanowski

Type II diabetes is a metabolic disease mediated through multiple molecular pathways. Here, we report anti-diabetic effect of a standardized isolate from a fossil material - a mineraloid leonardite - in in vitro tests and in genetically diabetic mice. The mineraloid isolate stimulated mitochondrial metabolism in human fibroblasts and this stimulation correlated with enhanced expression of genes coding for mitochondrial proteins such as ATP synthases and ribosomal protein precursors, as measured by DNA microarrays. In the diabetic animal model, consumption of the Totala isolate resulted in decreased weight gain, blood glucose, and glycated hemoglobin. To our best knowledge, this is the first description ever of a fossil material having anti-diabetic activity in pre-clinical models.


2006 ◽  
Vol 54 (S 1) ◽  
Author(s):  
HS Hofmann ◽  
A Simm ◽  
G Hansen ◽  
RJ Scheubel ◽  
RE Silber ◽  
...  

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
KM Sheehan ◽  
C Gulmann ◽  
HL Barrett ◽  
EW Kay ◽  
LA Liotta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document